Search results
Moffitt Cancer Center and Virogen Biotechnology Fo | Newswise
Newswise· 6 days agoTAMPA, Fla., and PLEASANTON, Calif. — Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Virogen Biotechnology ...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Tehachapi News· 3 days agoPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments< ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 days agoAdaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell ...
Scientists identify ‘missing piece’ required f | Newswise
Newswise· 1 day agoThe study, published in Nature, brings researchers one step closer to developing methods to expand...
J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 4 days agoWe all want a crystal ball, something that will let us peer a few months into the future and know...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 4 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
Celularity Inc. (NASDAQ:CELU) Sees Large Growth in Short Interest
ETF DAILY NEWS· 2 days agoCelularity Inc. (NASDAQ:CELU – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 627,100 shares, a growth of ...
Lawrence: Medications might increase your risk of skin cancer
The Pueblo Chieftain via Yahoo News· 5 days agoBy scheduling regular skin exams, you can catch any potential issues before they become more...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 3 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoProgress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered
